Heidelberg Pharma AG
HPHA
Rank in Stocks
#19388
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Share Price
$2.26
Last synced: 2026-11-18
Market Cap
$101.72M
Change (1 day)
-0.61%
Change (1 year)
-33.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Heidelberg Pharma AG (HPHA)
Category
Healthcare
P/B ratio for Heidelberg Pharma AG (HPHA)
P/B ratio as of November 2026 TTM: -4.86
According to Heidelberg Pharma AG's latest financial reports and stock price, its current price-to-book ratio (TTM) is -4.86. At the end of 2025 the company had a P/B ratio of -12.31.
P/B ratio history for Heidelberg Pharma AG from 2006 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | -4.86 | -60.51% |
| 2025 | -12.31 | -439.71% |
| 2024 | 3.62 | 39.03% |
| 2023 | 2.61 | -18.44% |
| 2022 | 3.20 | -87.28% |
| 2021 | 25.13 | 108.22% |
| 2020 | 12.07 | 215.47% |
| 2019 | 3.83 | 23.63% |
| 2018 | 3.09 | 192.03% |
| 2017 | 1.06 | -80.11% |
| 2016 | 5.33 | 230.82% |
| 2015 | 1.61 | 16.78% |
| 2014 | 1.38 | -55.44% |
| 2013 | 3.10 | 126.28% |
| 2012 | 1.37 | -101.48% |
| 2011 | -92.16 | 37.63% |
| 2010 | -66.96 | -412.94% |
| 2009 | 21.40 | 168.89% |
| 2008 | 7.96 | 203.78% |
| 2007 | 2.62 | -26.99% |
| 2006 | 3.59 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.5305 | -234.33% |
US
|
|
| 13.101 | -369.48% |
US
|
|
| 4.451 | -191.55% |
AU
|
|
| 4.8339 | -199.43% |
BE
|
|
| 7.2161 | -248.43% |
NL
|
Questions about Heidelberg Pharma AG's P/B ratio
What is Heidelberg Pharma AG's P/B ratio?
Heidelberg Pharma AG's P/B ratio is -4.86, as of Nov 2026.
What was Heidelberg Pharma AG's P/B ratio in 2025?
In 2025, Heidelberg Pharma AG's P/B ratio was -12.31, compared with 3.62 in 2024.
How has Heidelberg Pharma AG's P/B ratio changed since 2020?
From 2020 to 2025, Heidelberg Pharma AG's P/B ratio was highest in 2021 (25.13) and lowest in 2025 (-12.31).
How does Heidelberg Pharma AG's P/B ratio compare with similar companies?
Heidelberg Pharma AG's P/B ratio (-4.86) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 13.10.